# Jean Paul Jean Paul Thiery

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 353 papers | 43,544 citations | 91 h-index | 204 g-index |
| 381 ext. papers | 48,664 ext. citations | 8.3 avg, IF | 7.92 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 353 | A proposal to improve gene expression analysis. *Clinical and Translational Discovery*, **2022**, 2, | | |
| 352 | The Continuing Search for Causality between Epithelial-to-Mesenchymal Transition and the Metastatic Fitness of Carcinoma Cells.. *Cancer Research*, **2022**, 82, 1467-1469 | 10.1 | 0 |
| 351 | Intrinsic Differences in Spatiotemporal Organization and Stromal Cell Interactions Between Isogenic Lung Cancer Cells of Epithelial and Mesenchymal Phenotypes Revealed by High-Dimensional Single-Cell Analysis of Heterotypic 3D Spheroid Models.. *Frontiers in Oncology*, **2022**, 12, 818437 | 5.3 | 0 |
| 350 | Dissecting the Role of AXL in Cancer Immune Escape and Resistance to Immune Checkpoint Inhibition.. *Frontiers in Immunology*, **2022**, 13, 869676 | 8.4 | 3 |
| 349 | Osteopontin (OPN/SPP1), a Mediator of Tumor Progression, Is Regulated by the Mesenchymal Transcription Factor Slug/SNAI2 in Colorectal Cancer (CRC). *Cells*, **2022**, 11, 1808 | 7.9 | 1 |
| 348 | Cancer Biomarkers: A Long and Tortuous Journey **2022**, 563-580 | | |
| 347 | EMT: An Update. *Methods in Molecular Biology*, **2021**, 2179, 35-39 | 1.4 | 3 |
| 346 | Pirfenidone Reduces Epithelial-Mesenchymal Transition and Spheroid Formation in Breast Carcinoma through Targeting Cancer-Associated Fibroblasts (CAFs). *Cancers*, **2021**, 13, | 6.6 | 1 |
| 345 | Epithelial to Mesenchymal Transition Regulates Surface PD-L1 via CMTM6 and CMTM7 Induction in Breast Cancer. *Cancers*, **2021**, 13, | 6.6 | 6 |
| 344 | Fusion transcript discovery using RNA sequencing in formalin-fixed paraffin-embedded specimen. *Critical Reviews in Oncology/Hematology*, **2021**, 160, 103303 | 7 | 3 |
| 343 | Machine learning reveals mesenchymal breast carcinoma cell adaptation in response to matrix stiffness. *PLoS Computational Biology*, **2021**, 17, e1009193 | 5 | 1 |
| 342 | Harnessing Carcinoma Cell Plasticity Mediated by TGF-Signaling. *Cancers*, **2021**, 13, | 6.6 | 2 |
| 341 | Mesenchymal stem cells induce PD-L1 expression through the secretion of CCL5 in breast cancer cells. *Journal of Cellular Physiology*, **2021**, 236, 3918-3928 | 7 | 9 |
| 340 | Emerging role of circulating tumor cells in immunotherapy. *Theranostics*, **2021**, 11, 8057-8075 | 12.1 | 5 |
| 339 | Blocking Aerobic Glycolysis by Targeting Pyruvate Dehydrogenase Kinase in Combination with EGFR TKI and Ionizing Radiation Increases Therapeutic Effect in Non-Small Cell Lung Cancer Cells. *Cancers*, **2021**, 13, | 6.6 | 5 |
| 338 | High prevalence of APOA1/C3/A4/A5 alterations in luminal breast cancers among young women in East Asia. *Npj Breast Cancer*, **2021**, 7, 88 | 7.8 | 1 |
| 337 | Extracellular domains of E-cadherin determine key mechanical phenotypes of an epithelium through cell- and non-cell-autonomous outside-in signaling.. *PLoS ONE*, **2021**, 16, e0260593 | 3.7 | 0 |

| | | | |
|---|---|---|---|
| 336 | Pirfenidone reduces immune-suppressive capacity of cancer-associated fibroblasts through targeting CCL17 and TNF-beta. *Integrative Biology (United Kingdom)*, **2020**, 12, 188-197 | 3.7 | 15 |
| 335 | EMT signaling: potential contribution of CRISPR/Cas gene editing. *Cellular and Molecular Life Sciences*, **2020**, 77, 2701-2722 | 10.3 | 12 |
| 334 | AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells. *Journal of Thoracic Oncology*, **2020**, 15, 973-999 | 8.9 | 36 |
| 333 | Integrative Analysis and Machine Learning based Characterization of Single Circulating Tumor Cells. *Journal of Clinical Medicine*, **2020**, 9, | 5.1 | 16 |
| 332 | Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity. *EMBO Molecular Medicine*, **2020**, 12, e11908 | 12 | 35 |
| 331 | Decoding cancerR camouflage: epithelial-mesenchymal plasticity in resistance to immune checkpoint blockade. **2020**, 3, 832-853 | | 4 |
| 330 | Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer. *Clinical Cancer Research*, **2020**, 26, 242-255 | 12.9 | 55 |
| 329 | AXL Is a Driver of Stemness in Normal Mammary Gland and Breast Cancer. *IScience*, **2020**, 23, 101649 | 6.1 | 9 |
| 328 | Guidelines and definitions for research on epithelial-mesenchymal transition. *Nature Reviews Molecular Cell Biology*, **2020**, 21, 341-352 | 48.7 | 469 |
| 327 | Traditional Chinese Medicine and regulatory roles on epithelial-mesenchymal transitions. *Chinese Medicine*, **2019**, 14, 34 | 4.7 | 9 |
| 326 | c-Met activation leads to the establishment of a TGF□receptor regulatory network in bladder cancer progression. *Nature Communications*, **2019**, 10, 4349 | 17.4 | 25 |
| 325 | Phosphoproteomic Profiling Identifies Aberrant Activation of Integrin Signaling in Aggressive Non-Type Bladder Carcinoma. *Journal of Clinical Medicine*, **2019**, 8, | 5.1 | 11 |
| 324 | SNAI1 recruits HDAC1 to suppress SNAI2 transcription during epithelial to mesenchymal transition. *Scientific Reports*, **2019**, 9, 8295 | 4.9 | 15 |
| 323 | Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of. *Cancer & Metabolism*, **2019**, 7, 6 | 5.4 | 33 |
| 322 | PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein. *Nature Communications*, **2019**, 10, 2484 | 17.4 | 17 |
| 321 | Circulating Tumor Cell cluster phenotype allows monitoring response to treatment and predicts survival. *Scientific Reports*, **2019**, 9, 7933 | 4.9 | 29 |
| 320 | Epithelial-to-mesenchymal transition: lessons from development, insights into cancer and the potential of EMT-subtype based therapeutic intervention. *Physical Biology*, **2019**, 16, 041004 | 3 | 33 |
| 319 | Integrated use of bioinformatic resources reveals that co-targeting of histone deacetylases, IKBK and SRC inhibits epithelial-mesenchymal transition in cancer. *Briefings in Bioinformatics*, **2019**, 20, 717-731 | 13.4 | 13 |

| | | | |
|---|---|---|---|
| 318 | Upregulation of PD-L1 expression in breast cancer cells through the formation of 3D multicellular cancer aggregates under different chemical and mechanical conditions. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2019**, 1866, 118526 | 4.9 | 23 |
| 317 | Cell free circulating tumor nucleic acids, a revolution in personalized cancer medicine. *Critical Reviews in Oncology/Hematology*, **2019**, 144, 102827 | 7 | 13 |
| 316 | AXL Targeting Overcomes Human Lung Cancer Cell Resistance to NK- and CTL-Mediated Cytotoxicity. *Cancer Immunology Research*, **2019**, 7, 1789-1802 | 12.5 | 31 |
| 315 | Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors. *European Urology*, **2019**, 75, 423-432 | 10.2 | 120 |
| 314 | The FZD7-TWIST1 axis is responsible for anoikis resistance and tumorigenesis in ovarian carcinoma. *Molecular Oncology*, **2019**, 13, 757-780 | 7.9 | 11 |
| 313 | Mesenchymal-epithelial transition in development and reprogramming. *Nature Cell Biology*, **2019**, 21, 44-53 | 23.4 | 104 |
| 312 | Reply to Pontus Eriksson and Gottfrid Sjödahl's Letter to the Editor re: Tuan Zea Tan, Mathieu Rouanne, Kien Thiam Tan, Ruby Yun-Ju Huang, Jean-Paul Thiery. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors. Eur Urol 2019;75:423-32. *European Urology*, **2019**, 75, e108-e109 | 10.2 | 4 |
| 311 | Engineered commensal microbes for diet-mediated colorectal-cancer chemoprevention. *Nature Biomedical Engineering*, **2018**, 2, 27-37 | 19 | 106 |
| 310 | CD47 is a direct target of SNAI1 and ZEB1 and its blockade activates the phagocytosis of breast cancer cells undergoing EMT. *OncoImmunology*, **2018**, 7, e1345415 | 7.2 | 42 |
| 309 | TGFβ Promotes Genomic Instability after Loss of RUNX3. *Cancer Research*, **2018**, 78, 88-102 | 10.1 | 17 |
| 308 | Tricho-rhino-phalangeal syndrome 1 protein functions as a scaffold required for ubiquitin-specific protease 4-directed histone deacetylase 2 de-ubiquitination and tumor growth. *Breast Cancer Research*, **2018**, 20, 83 | 8.3 | 9 |
| 307 | Actin Cytoskeleton Remodeling Drives Breast Cancer Cell Escape from Natural Killer-Mediated Cytotoxicity. *Cancer Research*, **2018**, 78, 5631-5643 | 10.1 | 62 |
| 306 | The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer. *EMBO Reports*, **2018**, 19, | 6.5 | 20 |
| 305 | Probing compression versus stretch activated recruitment of cortical actin and apical junction proteins using mechanical stimulations of suspended doublets. *APL Bioengineering*, **2018**, 2, 026111 | 6.6 | 6 |
| 304 | A combined microfluidic-transcriptomic approach to characterize the extravasation potential of cancer cells. *Oncotarget*, **2018**, 9, 36110-36125 | 3.3 | 17 |
| 303 | The prognostic significance of circulating tumor cells in head and neck and non-small-cell lung cancer. *Cancer Medicine*, **2018**, 7, 5910-5919 | 4.8 | 66 |
| 302 | DNA Methylation Profiling of Breast Cancer Cell Lines along the Epithelial Mesenchymal Spectrum-Implications for the Choice of Circulating Tumour DNA Methylation Markers. *International Journal of Molecular Sciences*, **2018**, 19, | 6.3 | 9 |
| 301 | The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200. *OncoImmunology*, **2017**, 6, e1263412 | 7.2 | 136 |

| | | | |
|---|---|---|---|
| 300 | Acquisition of tumor cell phenotypic diversity along the EMT spectrum under hypoxic pressure: Consequences on susceptibility to cell-mediated cytotoxicity. *OncoImmunology*, **2017**, 6, e1271858 | 7.2 | 49 |
| 299 | Transposon insertional mutagenesis in mice identifies human breast cancer susceptibility genes and signatures for stratification. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, E2215-E2224 | 11.5 | 24 |
| 298 | The EMT spectrum and therapeutic opportunities. *Molecular Oncology*, **2017**, 11, 878-891 | 7.9 | 59 |
| 297 | New insights into the role of EMT in tumor immune escape. *Molecular Oncology*, **2017**, 11, 824-846 | 7.9 | 180 |
| 296 | The Emerging Roles of RUNX Transcription Factors in Epithelial-Mesenchymal Transition. *Advances in Experimental Medicine and Biology*, **2017**, 962, 471-489 | 3.6 | 5 |
| 295 | Targeting HSP90-HDAC6 Regulating Network Implicates Precision Treatment of Breast Cancer. *International Journal of Biological Sciences*, **2017**, 13, 505-517 | 11.2 | 25 |
| 294 | Molecular characterization of breast cancer CTCs associated with brain metastasis. *Nature Communications*, **2017**, 8, 196 | 17.4 | 103 |
| 293 | Clear Cell Renal Cell Carcinoma is linked to Epithelial-to-Mesenchymal Transition and to Fibrosis. *Physiological Reports*, **2017**, 5, e13305 | 2.6 | 21 |
| 292 | Microdevices for Non-Invasive Detection of Bladder Cancer. *Chemosensors*, **2017**, 5, 30 | 4 | 7 |
| 291 | Manganese Superoxide Dismutase Expression Regulates the Switch Between an Epithelial and a Mesenchymal-Like Phenotype in Breast Carcinoma. *Antioxidants and Redox Signaling*, **2016**, 25, 283-99 | 8.4 | 32 |
| 290 | TRPV4 Regulates Breast Cancer Cell Extravasation, Stiffness and Actin Cortex. *Scientific Reports*, **2016**, 6, 27903 | 4.9 | 75 |
| 289 | The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer. *Science Signaling*, **2016**, 9, ra97 | 8.8 | 76 |
| 288 | Liquid biopsy and therapeutic response: Circulating tumor cell cultures for evaluation of anticancer treatment. *Science Advances*, **2016**, 2, e1600274 | 14.3 | 78 |
| 287 | GRHL2-miR-200-ZEB1 maintains the epithelial status of ovarian cancer through transcriptional regulation and histone modification. *Scientific Reports*, **2016**, 6, 19943 | 4.9 | 88 |
| 286 | Extracellular matrix scaffolding guides lumen elongation by inducing anisotropic intercellular mechanical tension. *Nature Cell Biology*, **2016**, 18, 311-8 | 23.4 | 51 |
| 285 | Genesis of Circulating Tumor Cells Through Epithelial Mesenchymal Transition as a Mechanism for Distant Dissemination. *Current Cancer Research*, **2016**, 139-182 | 0.2 | 2 |
| 284 | Intraoperative cell salvage in metastatic spine tumour surgery reduces potential for reinfusion of viable cancer cells. *European Spine Journal*, **2016**, 25, 4008-4015 | 2.7 | 14 |
| 283 | Impact of label-free technologies in head and neck cancer circulating tumour cells. *Oncotarget*, **2016**, 7, 71223-71234 | 3.3 | 23 |

| | | | |
|---|---|---|---|
| 282 | PRL3-zumab, a first-in-class humanized antibody for cancer therapy. *JCI Insight*, **2016**, 1, e87607 | 9.9 | 32 |
| 281 | Identification of 42 Genes Linked to Stage II Colorectal Cancer Metastatic Relapse. *International Journal of Molecular Sciences*, **2016**, 17, | 6.3 | 9 |
| 280 | EMT: 2016. *Cell*, **2016**, 166, 21-45 | 56.2 | 2443 |
| 279 | Functional characterization of selective exosite-binding inhibitors of matrix metalloproteinase-13 (MMP-13) - experimental validation in human breast and colon cancer. *Bioscience, Biotechnology and Biochemistry*, **2016**, 80, 2122-2131 | 2.1 | 2 |
| 278 | RNormalizingRthe malignant phenotype of luminal breast cancer cells via alpha(v)beta(3)-integrin. *Cell Death and Disease*, **2016**, 7, e2491 | 9.8 | 12 |
| 277 | Microfluidic models for adoptive cell-mediated cancer immunotherapies. *Drug Discovery Today*, **2016**, 21, 1472-1478 | 8.8 | 48 |
| 276 | Exosome-Mediated Metastasis: From Epithelial-Mesenchymal Transition to Escape from Immunosurveillance. *Trends in Pharmacological Sciences*, **2016**, 37, 606-617 | 13.2 | 298 |
| 275 | TIP60 inhibits metastasis by ablating DNMT1-SNAIL2-driven epithelial-mesenchymal transition program. *Journal of Molecular Cell Biology*, **2016**, 8, 384-399 | 6.3 | 12 |
| 274 | Mach-Zehnder interferometer (MZI) point-of-care system for rapid multiplexed detection of microRNAs in human urine specimens. *Biosensors and Bioelectronics*, **2015**, 71, 365-372 | 11.8 | 43 |
| 273 | Pentimento: Neural Crest and the origin of mesectoderm. *Developmental Biology*, **2015**, 401, 37-61 | 3.1 | 41 |
| 272 | Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib. *Journal of Translational Medicine*, **2015**, 13, 57 | 8.5 | 42 |
| 271 | MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma. *Molecular Cancer Therapeutics*, **2015**, 14, 1750-60 | 6.1 | 36 |
| 270 | Homophilic interaction and deformation of E-cadherin and cadherin 7 probed by single molecule force spectroscopy. *Archives of Biochemistry and Biophysics*, **2015**, 587, 38-47 | 4.1 | 2 |
| 269 | The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions. *Human Pathology*, **2015**, 46, 1-8 | 3.7 | 42 |
| 268 | Noncanonical roles of membranous lysyl-tRNA synthetase in transducing cell-substrate signaling for invasive dissemination of colon cancer spheroids in 3D collagen I gels. *Oncotarget*, **2015**, 6, 21655-74 | 3.3 | 15 |
| 267 | Highly sensitive and specific novel biomarkers for the diagnosis of transitional bladder carcinoma. *Oncotarget*, **2015**, 6, 13539-49 | 3.3 | 53 |
| 266 | RKIP regulates CCL5 expression to inhibit breast cancer invasion and metastasis by controlling macrophage infiltration. *Oncotarget*, **2015**, 6, 39050-61 | 3.3 | 30 |
| 265 | CSIOVDB: a microarray gene expression database of epithelial ovarian cancer subtype. *Oncotarget*, **2015**, 6, 43843-52 | 3.3 | 46 |

| | | | |
|---|---|---|---|
| 264 | Molecular portraits of epithelial, mesenchymal, and hybrid States in lung adenocarcinoma and their relevance to survival. *Cancer Research*, **2015**, 75, 1789-800 | 10.1 | 128 |
| 263 | Adhesion glycoprotein CD44 functions as an upstream regulator of a network connecting ERK, AKT and Hippo-YAP pathways in cancer progression. *Oncotarget*, **2015**, 6, 2951-65 | 3.3 | 43 |
| 262 | Short-term expansion of breast circulating cancer cells predicts response to anti-cancer therapy. *Oncotarget*, **2015**, 6, 15578-93 | 3.3 | 103 |
| 261 | Chronic chemotherapeutic stress promotes evolution of stemness and WNT/beta-catenin signaling in colorectal cancer cells: implications for clinical use of WNT-signaling inhibitors. *Oncotarget*, **2015**, 6, 18518-33 | 3.3 | 21 |
| 260 | Functional relevance of a six mesenchymal gene signature in epithelial-mesenchymal transition (EMT) reversal by the triple angiokinase inhibitor, nintedanib (BIBF1120). *Oncotarget*, **2015**, 6, 22098-113 | 3.3 | 36 |
| 259 | Contact-dependent carcinoma aggregate dispersion by M2a macrophages via ICAM-1 and β2 integrin interactions. *Oncotarget*, **2015**, 6, 25295-307 | 3.3 | 80 |
| 258 | Combinatorial treatment using targeted MEK and SRC inhibitors synergistically abrogates tumor cell growth and induces mesenchymal-epithelial transition in non-small-cell lung carcinoma. *Oncotarget*, **2015**, 6, 29991-30005 | 3.3 | 12 |
| 257 | Identification of drugs as single agents or in combination to prevent carcinoma dissemination in a microfluidic 3D environment. *Oncotarget*, **2015**, 6, 36603-14 | 3.3 | 50 |
| 256 | Epithelial Mesenchymal Transition Influence on CTL Activity. *Resistance To Targeted Anti-cancer Therapeutics*, **2015**, 267-284 | 0.3 | |
| 255 | Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients. *EMBO Molecular Medicine*, **2014**, 6, 1279-93 | 12 | 399 |
| 254 | DEAD-box helicase DP103 defines metastatic potential of human breast cancers. *Journal of Clinical Investigation*, **2014**, 124, 3807-24 | 15.9 | 98 |
| 253 | Loss of β-catenin elicits a cholestatic response and impairs liver regeneration. *Scientific Reports*, **2014**, 4, 6835 | 4.9 | 31 |
| 252 | Tumor plasticity interferes with anti-tumor immunity. *Critical Reviews in Immunology*, **2014**, 34, 91-102 | 1.8 | 34 |
| 251 | A role of autophagy in PTP4A3-driven cancer progression. *Autophagy*, **2014**, 10, 1787-800 | 10.2 | 35 |
| 250 | Drug Screening: Rapid Prototyping of Concave Microwells for the Formation of 3D Multicellular Cancer Aggregates for Drug Screening (Adv. Healthcare Mater. 4/2014). *Advanced Healthcare Materials*, **2014**, 3, 620-620 | 10.1 | |
| 249 | Raf kinase inhibitory protein role in the molecular subtyping of breast cancer. *Journal of Cellular Biochemistry*, **2014**, 115, 488-97 | 4.7 | 9 |
| 248 | Meta-analysis of transcriptome reveals let-7b as an unfavorable prognostic biomarker and predicts molecular and clinical subclasses in high-grade serous ovarian carcinoma. *International Journal of Cancer*, **2014**, 134, 306-18 | 7.5 | 53 |
| 247 | Manganese superoxide dismutase is a promising target for enhancing chemosensitivity of basal-like breast carcinoma. *Antioxidants and Redox Signaling*, **2014**, 20, 2326-46 | 8.4 | 31 |

| | | | |
|---|---|---|---|
| 246 | Rapid prototyping of concave microwells for the formation of 3D multicellular cancer aggregates for drug screening. *Advanced Healthcare Materials*, **2014**, 3, 609-16 | 10.1 | 58 |
| 245 | SPHK1 regulates proliferation and survival responses in triple-negative breast cancer. *Oncotarget*, **2014**, 5, 5920-33 | 3.3 | 60 |
| 244 | A central role for TRPS1 in the control of cell cycle and cancer development. *Oncotarget*, **2014**, 5, 7677-90 | 3.3 | 35 |
| 243 | Dermal fin rays and scales derive from mesoderm, not neural crest. *Current Biology*, **2013**, 23, R336-7 | 6.3 | 54 |
| 242 | Screening therapeutic EMT blocking agents in a three-dimensional microenvironment. *Integrative Biology (United Kingdom)*, **2013**, 5, 381-9 | 3.7 | 123 |
| 241 | Remarkable disparity in mechanical response among the extracellular domains of type I and II cadherins. *Journal of Biomolecular Structure and Dynamics*, **2013**, 31, 1137-49 | 3.6 | 5 |
| 240 | Microfluidic cell trap array for controlled positioning of single cells on adhesive micropatterns. *Lab on A Chip*, **2013**, 13, 714-21 | 7.2 | 61 |
| 239 | Tumor dissemination: an EMT affair. *Cancer Cell*, **2013**, 23, 272-3 | 24.3 | 154 |
| 238 | Epithelial-to-mesenchymal transition and autophagy induction in breast carcinoma promote escape from T-cell-mediated lysis. *Cancer Research*, **2013**, 73, 2418-27 | 10.1 | 211 |
| 237 | Translating metastasis-related biomarkers to the clinic--progress and pitfalls. *Nature Reviews Clinical Oncology*, **2013**, 10, 169-79 | 19.4 | 35 |
| 236 | Loss of Git2 induces epithelial-mesenchymal transition by miR146a-Cnot6L-controlled expression of Zeb1. *Journal of Cell Science*, **2013**, 126, 2740-6 | 5.3 | 12 |
| 235 | An exclusively mesodermal origin of fin mesenchyme demonstrates that zebrafish trunk neural crest does not generate ectomesenchyme. *Development (Cambridge)*, **2013**, 140, 2923-32 | 6.6 | 63 |
| 234 | EMT impairs breast carcinoma cell susceptibility to CTL-mediated lysis through autophagy induction. *Autophagy*, **2013**, 9, 1104-6 | 10.2 | 48 |
| 233 | □Catenin and vinculin cooperate to promote high E-cadherin-based adhesion strength. *Journal of Biological Chemistry*, **2013**, 288, 4957-69 | 5.4 | 114 |
| 232 | How to discriminate between potentially novel and considered biomarkers within molecular signature? **2013**, | | 1 |
| 231 | Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer. *EMBO Molecular Medicine*, **2013**, 5, 1051-66 | 12 | 178 |
| 230 | Cell delamination in the mesencephalic neural fold and its implication for the origin of ectomesenchyme. *Development (Cambridge)*, **2013**, 140, 4890-902 | 6.6 | 43 |
| 229 | □catenin, vinculin, and F-actin in strengthening E-cadherin cell-cell adhesions and mechanosensing. *Cell Adhesion and Migration*, **2013**, 7, 345-50 | 3.2 | 32 |

| | | | |
|---|---|---|---|
| 228 | Clinical implications for loss or diminution of expression of Raf-1 kinase inhibitory protein and its phosphorylated form in ductal breast cancer. *American Journal of Cancer Research*, **2013**, 3, 446-64 | 4.4 | 11 |
| 227 | Early events in cell adhesion and polarity during epithelial-mesenchymal transition. *Journal of Cell Science*, **2012**, 125, 4417-22 | 5.3 | 222 |
| 226 | The first World Cell Race. *Current Biology*, **2012**, 22, R673-5 | 6.3 | 104 |
| 225 | Biochemical and biophysical origins of cadherin selectivity and adhesion strength. *Current Opinion in Cell Biology*, **2012**, 24, 614-9 | 9 | 23 |
| 224 | Histotype-specific copy-number alterations in ovarian cancer. *BMC Medical Genomics*, **2012**, 5, 47 | 3.7 | 35 |
| 223 | Runx3 protects gastric epithelial cells against epithelial-mesenchymal transition-induced cellular plasticity and tumorigenicity. *Stem Cells*, **2012**, 30, 2088-99 | 5.8 | 69 |
| 222 | Gene expression analysis of matched ovarian primary tumors and peritoneal metastasis. *Journal of Translational Medicine*, **2012**, 10, 121 | 8.5 | 20 |
| 221 | Epithelial-mesenchymal transitions: insights from development. *Development (Cambridge)*, **2012**, 139, 3471-86 | 6.6 | 464 |
| 220 | Targeting pathways contributing to epithelial-mesenchymal transition (EMT) in epithelial ovarian cancer. *Current Drug Targets*, **2012**, 13, 1649-53 | 3 | 63 |
| 219 | A cell-based small molecule screening method for identifying inhibitors of epithelial-mesenchymal transition in carcinoma. *PLoS ONE*, **2012**, 7, e33183 | 3.7 | 64 |
| 218 | SnapShot: The epithelial-mesenchymal transition. *Cell*, **2011**, 145, 162.e1 | 56.2 | 80 |
| 217 | Alternative path to EMT: regulation of apicobasal polarity in Drosophila. *Developmental Cell*, **2011**, 21, 983-4 | 10.2 | 9 |
| 216 | Target cell movement in tumor and cardiovascular diseases based on the epithelial-mesenchymal transition concept. *Advanced Drug Delivery Reviews*, **2011**, 63, 558-67 | 18.5 | 36 |
| 215 | Micropatterns of cell adhesive proteins with poly(ethylene oxide)-block-Poly(4-vinylpyridine) diblock copolymer. *Biotechnology and Bioengineering*, **2011**, 108, 983-7 | 4.9 | 5 |
| 214 | High PTP4A3 phosphatase expression correlates with metastatic risk in uveal melanoma patients. *Cancer Research*, **2011**, 71, 666-74 | 10.1 | 96 |
| 213 | Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor. *PLoS Biology*, **2011**, 9, e1001162 | 9.7 | 239 |
| 212 | Copy number variation analysis of matched ovarian primary tumors and peritoneal metastasis. *PLoS ONE*, **2011**, 6, e28561 | 3.7 | 38 |
| 211 | Integrins stimulate E-cadherin-mediated intercellular adhesion by regulating Src-kinase activation and actomyosin contractility. *Journal of Cell Science*, **2010**, 123, 712-22 | 5.3 | 118 |

| | | | |
|---|---|---|---|
| 210 | A Versatile Gradient of Biomolecules for Regulating Cell Behaviour. *Journal of Adhesion Science and Technology*, **2010**, 24, 975-992 | 2 | 3 |
| 209 | Phospho-Akt pathway activation and inhibition depends on N-cadherin or phospho-EGFR expression in invasive human bladder cancer cell lines. *Urologic Oncology: Seminars and Original Investigations*, **2010**, 28, 180-8 | 2.8 | 32 |
| 208 | Integrins stimulate E-cadherin-mediated intercellular adhesion by regulating Src-kinase activation and actomyosin contractility. *Development (Cambridge)*, **2010**, 137, e1-e1 | 6.6 | |
| 207 | Beta1 integrins are required for the invasion of the caecum and proximal hindgut by enteric neural crest cells. *Development (Cambridge)*, **2009**, 136, 2791-801 | 6.6 | 64 |
| 206 | Evaluation of methods for amplification of picogram amounts of total RNA for whole genome expression profiling. *BMC Genomics*, **2009**, 10, 246 | 4.5 | 52 |
| 205 | Metastasis: alone or together?. *Current Biology*, **2009**, 19, R1121-3 | 6.3 | 24 |
| 204 | Genomic profiling and identification of high-risk uveal melanoma by array CGH analysis of primary tumors and liver metastases **2009**, 50, 2572-80 | | 107 |
| 203 | Epithelial-mesenchymal transitions in development and disease. *Cell*, **2009**, 139, 871-90 | 56.2 | 7255 |
| 202 | The expression of Twist has an impact on survival in human bladder cancer and is influenced by the smoking status. *Urologic Oncology: Seminars and Original Investigations*, **2009**, 27, 268-76 | 2.8 | 58 |
| 201 | Role of E-cadherin in membrane-cortex interaction probed by nanotube extrusion. *Biophysical Journal*, **2009**, 96, 2457-65 | 2.9 | 23 |
| 200 | Epithelial to mesenchymal transition and breast cancer. *Breast Cancer Research*, **2009**, 11, 213 | 8.3 | 214 |
| 199 | Fabrication of Adhesive Protein Micropatterns In Application of Studying Cell Surface Interactions. *IFMBE Proceedings*, **2009**, 1980-1983 | 0.2 | |
| 198 | Transitions þithłium m§enchyme dans le dveloppement et la progression des carcinomes. *Bulletin De LhAcademie Nationale De Medecine*, **2009**, 193, 1969-1979 | 0.1 | 7 |
| 197 | The physiology and pathology of the EMT. Meeting on the epithelial-mesenchymal transition. *EMBO Reports*, **2008**, 9, 322-6 | 6.5 | 85 |
| 196 | Beta1 integrin deletion from the basal compartment of the mammary epithelium affects stem cells. *Nature Cell Biology*, **2008**, 10, 716-22 | 23.4 | 198 |
| 195 | Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells. *Breast Cancer Research*, **2008**, 10, R101 | 8.3 | 168 |
| 194 | High-resolution mapping of DNA breakpoints to define true recurrences among ipsilateral breast cancers. *Journal of the National Cancer Institute*, **2008**, 100, 48-58 | 9.7 | 54 |
| 193 | A nonneural epithelial domain of embryonic cranial neural folds gives rise to ectomesenchyme. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 7750-5 | 11.5 | 35 |

| | | | |
|---|---|---|---|
| 192 | Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse. *Clinical Cancer Research*, **2008**, 14, 3306-11 | 12.9 | 115 |
| 191 | Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast. *Clinical Cancer Research*, **2008**, 14, 1956-65 | 12.9 | 130 |
| 190 | Wnt11r is required for cranial neural crest migration. *Developmental Dynamics*, **2008**, 237, 3404-9 | 2.9 | 34 |
| 189 | Modulation of several waves of gene expression during FGF-1 induced epithelial-mesenchymal transition of carcinoma cells. *Journal of Cellular Biochemistry*, **2008**, 104, 826-39 | 4.7 | 47 |
| 188 | Differential regulation of the lateral mobility of plasma membrane phospholipids by the extracellular matrix and cholesterol. *Journal of Cellular Physiology*, **2008**, 215, 550-61 | 7 | 3 |
| 187 | Targeted therapies in control of EMT in carcinoma and fibrosis. *Drug Discovery Today Disease Mechanisms*, **2007**, 4, 261-267 | | 19 |
| 186 | Regulation of XSnail2 expression by Rho GTPases. *Developmental Dynamics*, **2007**, 236, 2555-66 | 2.9 | 29 |
| 185 | Changes in cholesterol levels in the plasma membrane modulate cell signaling and regulate cell adhesion and migration on fibronectin. *Cytoskeleton*, **2007**, 64, 199-216 | | 62 |
| 184 | The universal dynamics of cell spreading. *Current Biology*, **2007**, 17, 694-9 | 6.3 | 204 |
| 183 | Pre-EMTing metastasis? Recapitulation of morphogenetic processes in cancer. *Clinical and Experimental Metastasis*, **2007**, 24, 587-97 | 4.7 | 191 |
| 182 | beta-Catenin regulates P-cadherin expression in mammary basal epithelial cells. *FEBS Letters*, **2007**, 581, 831-6 | 3.8 | 18 |
| 181 | Lack of beta1 integrins in enteric neural crest cells leads to a Hirschsprung-like phenotype. *Development (Cambridge)*, **2006**, 133, 1725-34 | 6.6 | 84 |
| 180 | Prototypical type I E-cadherin and type II cadherin-7 mediate very distinct adhesiveness through their extracellular domains. *Journal of Biological Chemistry*, **2006**, 281, 2901-10 | 5.4 | 92 |
| 179 | Gli3-mediated somitic Fgf10 expression gradients are required for the induction and patterning of mammary epithelium along the embryonic axes. *Development (Cambridge)*, **2006**, 133, 2325-35 | 6.6 | 92 |
| 178 | Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. *Carcinogenesis* , **2006**, 27, 740-7 | 4.6 | 111 |
| 177 | Neural crest-derived cells with stem cell features can be traced back to multiple lineages in the adult skin. *Journal of Cell Biology*, **2006**, 175, 1005-15 | 7.3 | 267 |
| 176 | Gefitinib inhibits the growth and invasion of urothelial carcinoma cell lines in which Akt and MAPK activation is dependent on constitutive epidermal growth factor receptor activation. *Clinical Cancer Research*, **2006**, 12, 2937-43 | 12.9 | 13 |
| 175 | Isolation of mouse mammary epithelial progenitor cells with basal characteristics from the Comma-Dbeta cell line. *Developmental Biology*, **2006**, 293, 414-25 | 3.1 | 70 |

| | | | |
|---|---|---|---|
| 174 | Regional copy number-independent deregulation of transcription in cancer. *Nature Genetics*, **2006**, 38, 1386-96 | 36.3 | 170 |
| 173 | Complex networks orchestrate epithelial-mesenchymal transitions. *Nature Reviews Molecular Cell Biology*, **2006**, 7, 131-42 | 48.7 | 3153 |
| 172 | Targeted activation of beta-catenin signaling in basal mammary epithelial cells affects mammary development and leads to hyperplasia. *Development (Cambridge)*, **2005**, 132, 267-77 | 6.6 | 125 |
| 171 | Johnson-Kendall-Roberts theory applied to living cells. *Physical Review Letters*, **2005**, 94, 028102 | 7.4 | 140 |
| 170 | Linking epithelial-mesenchymal transition to the well-known polarity protein Par6. *Developmental Cell*, **2005**, 8, 456-8 | 10.2 | 28 |
| 169 | Clinical and biological characteristics of cervical neoplasias with FGFR3 mutation. *Molecular Cancer*, **2005**, 4, 15 | 42.1 | 53 |
| 168 | Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens. *Carcinogenesis*, **2005**, 26, 177-84 | 4.6 | 62 |
| 167 | Identification of a proliferation gene cluster associated with HPV E6/E7 expression level and viral DNA load in invasive cervical carcinoma. *Oncogene*, **2005**, 24, 7094-104 | 9.2 | 110 |
| 166 | Real-time quantitative PCR determination of urokinase-type plasminogen activator receptor (uPAR) expression of isolated micrometastatic cells from bone marrow of breast cancer patients. *International Journal of Cancer*, **2005**, 114, 291-8 | 7.5 | 43 |
| 165 | Absence of FGFR3 mutations in urinary bladder tumours of rats and mice treated with N-butyl-N-(4-hydroxybutyl)nitrosamine. *Molecular Carcinogenesis*, **2005**, 42, 142-9 | 5 | 3 |
| 164 | Myoepithelial cells in the control of mammary development and tumorigenesis: data from genetically modified mice. *Journal of Mammary Gland Biology and Neoplasia*, **2005**, 10, 211-9 | 2.4 | 30 |
| 163 | Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. *Human Molecular Genetics*, **2005**, 14, 1153-60 | 5.6 | 151 |
| 162 | Identifying genes from up-down properties of microarray expression series. *Bioinformatics*, **2005**, 21, 3859-64 | 7.2 | 20 |
| 161 | Separation force measurements reveal different types of modulation of E-cadherin-based adhesion by nectin-1 and -3. *Journal of Biological Chemistry*, **2005**, 280, 4753-60 | 5.4 | 49 |
| 160 | Fgf10 expression identifies parabronchial smooth muscle cell progenitors and is required for their entry into the smooth muscle cell lineage. *Development (Cambridge)*, **2005**, 132, 2157-66 | 6.6 | 151 |
| 159 | Visualizing chromosomes as transcriptome correlation maps: evidence of chromosomal domains containing co-expressed genes--a study of 130 invasive ductal breast carcinomas. *Cancer Research*, **2005**, 65, 1376-83 | 10.1 | 58 |
| 158 | YY1 regulates the neural crest-associated slug gene in Xenopus laevis. *Journal of Biological Chemistry*, **2004**, 279, 46826-34 | 5.4 | 31 |
| 157 | Targets of fibroblast growth factor 1 (FGF-1) and FGF-2 signaling involved in the invasive and tumorigenic behavior of carcinoma cells. *Molecular Biology of the Cell*, **2004**, 15, 4725-34 | 3.5 | 39 |

| | | | |
|---|---|---|---|
| 156 | Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients. *Clinical Cancer Research*, **2004**, 10, 1392-400 | 12.9 | 210 |
| 155 | Conditional beta1-integrin gene deletion in neural crest cells causes severe developmental alterations of the peripheral nervous system. *Development (Cambridge)*, **2004**, 131, 3871-83 | 6.6 | 57 |
| 154 | Force measurements in E-cadherin-mediated cell doublets reveal rapid adhesion strengthened by actin cytoskeleton remodeling through Rac and Cdc42. *Journal of Cell Biology*, **2004**, 167, 1183-94 | 7.3 | 326 |
| 153 | Direct FGF receptor 1 activation through an anti-idiotypic strategy mimicks the biological activity of FGF-2 and inhibits the progression of the bladder carcinoma derived from NBT-II cells. *Oncogene*, **2004**, 23, 6769-78 | 9.2 | 4 |
| 152 | Nuclear FGF-2 facilitates cell survival in vitro and during establishment of metastases. *Oncogene*, **2004**, 23, 4771-9 | 9.2 | 35 |
| 151 | Inhibition of human bladder tumour cell growth by fibroblast growth factor receptor 2b is independent of its kinase activity. Involvement of the carboxy-terminal region of the receptor. *Oncogene*, **2004**, 23, 9201-11 | 9.2 | 34 |
| 150 | Growth, differentiation and senescence of normal human urothelium in an organ-like culture. *European Urology*, **2004**, 45, 799-805 | 10.2 | 24 |
| 149 | Gene expression analysis by real-time reverse transcription polymerase chain reaction: influence of tissue handling. *Analytical Biochemistry*, **2004**, 328, 101-8 | 3.1 | 74 |
| 148 | A relevant immunomagnetic assay to detect and characterize epithelial cell adhesion molecule-positive cells in bone marrow from patients with breast carcinoma: immunomagnetic purification of micrometastases. *Cancer*, **2004**, 101, 693-703 | 6.4 | 35 |
| 147 | Identification of the mammary line in mouse by Wnt10b expression. *Developmental Dynamics*, **2004**, 229, 349-56 | 2.9 | 102 |
| 146 | Analysis of array CGH data: from signal ratio to gain and loss of DNA regions. *Bioinformatics*, **2004**, 20, 3413-22 | 7.2 | 429 |
| 145 | Enrichment methods to detect bone marrow micrometastases in breast carcinoma patients: clinical relevance. *Breast Cancer Research*, **2004**, 6, R556-70 | 8.3 | 33 |
| 144 | Profiles of the 2 INK4a gene products, p16 and p14ARF, in human reference urothelium and bladder carcinomas, according to pRb and p53 protein status. *Human Pathology*, **2004**, 35, 817-24 | 3.7 | 21 |
| 143 | Integrins in mammary gland development and differentiation of mammary epithelium. *Journal of Mammary Gland Biology and Neoplasia*, **2003**, 8, 383-94 | 2.4 | 75 |
| 142 | Mouse embryonic mammogenesis as a model for the molecular regulation of pattern formation. *Differentiation*, **2003**, 71, 1-17 | 3.5 | 172 |
| 141 | Epithelial-mesenchymal transitions in development and pathologies. *Current Opinion in Cell Biology*, **2003**, 15, 740-6 | 9 | 1425 |
| 140 | Differential expression of beta3 integrin gene in chick and mouse cranial neural crest cells. *Developmental Dynamics*, **2003**, 227, 309-13 | 2.9 | 15 |
| 139 | Cell adhesion in cancer. *Comptes Rendus Physique*, **2003**, 4, 289-304 | 1.4 | 18 |

| | | | |
|---|---|---|---|
| 138 | Epidermal growth factor receptor regulates normal urothelial regeneration. *Laboratory Investigation*, **2003**, 83, 1333-41 | 5.9 | 29 |
| 137 | The human tissue plasminogen activator-Cre mouse: a new tool for targeting specifically neural crest cells and their derivatives in vivo. *Developmental Biology*, **2003**, 259, 176-87 | 3.1 | 118 |
| 136 | Cell adhesion in development: a complex signaling network. *Current Opinion in Genetics and Development*, **2003**, 13, 365-71 | 4.9 | 98 |
| 135 | Tube or not tube: remodeling epithelial tissues by branching morphogenesis. *Developmental Cell*, **2003**, 4, 11-8 | 10.2 | 228 |
| 134 | Host microenvironment in breast cancer development: epithelial-mesenchymal transition in breast cancer development. *Breast Cancer Research*, **2003**, 5, 101-6 | 8.3 | 169 |
| 133 | Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders. *European Journal of Human Genetics*, **2002**, 10, 819-24 | 5.3 | 121 |
| 132 | Rapid tumor development and potent vascularization are independent events in carcinoma producing FGF-1 or FGF-2. *Oncogene*, **2002**, 21, 8128-39 | 9.2 | 34 |
| 131 | Epithelial-mesenchymal transitions in tumour progression. *Nature Reviews Cancer*, **2002**, 2, 442-54 | 31.3 | 5249 |
| 130 | Fast dissociation kinetics between individual E-cadherin fragments revealed by flow chamber analysis. *EMBO Journal*, **2002**, 21, 2537-46 | 13 | 72 |
| 129 | EGF controls the in vivo developmental potential of a mammary epithelial cell line possessing progenitor properties. *Journal of Cell Biology*, **2002**, 159, 453-63 | 7.3 | 40 |
| 128 | Perturbation of beta1-integrin function in involuting mammary gland results in premature dedifferentiation of secretory epithelial cells. *Molecular Biology of the Cell*, **2002**, 13, 3521-31 | 3.5 | 35 |
| 127 | The importance of being a myoepithelial cell. *Breast Cancer Research*, **2002**, 4, 224-30 | 8.3 | 113 |
| 126 | Role of FGF10/FGFR2b signaling during mammary gland development in the mouse embryo. *Development (Cambridge)*, **2002**, 129, 53-60 | 6.6 | 162 |
| 125 | Ras induces NBT-II epithelial cell scattering through the coordinate activities of Rac and MAPK pathways. *Journal of Cell Science*, **2002**, 115, 2591-2601 | 5.3 | 65 |
| 124 | Design, synthesis and preliminary biological evaluation of a focused combinatorial library of stereodiverse carbohydrate-scaffold-based peptidomimetics. *Bioorganic and Medicinal Chemistry*, **2001**, 9, 511-23 | 3.4 | 44 |
| 123 | Growth defects induced by perturbation of beta1-integrin function in the mammary gland epithelium result from a lack of MAPK activation via the Shc and Akt pathways. *EMBO Reports*, **2001**, 2, 431-7 | 6.5 | 52 |
| 122 | No evidence of somatic FGFR3 mutation in various types of carcinoma. *Oncogene*, **2001**, 20, 5059-61 | 9.2 | 37 |
| 121 | IGF-II induces rapid beta-catenin relocation to the nucleus during epithelium to mesenchyme transition. *Oncogene*, **2001**, 20, 4942-50 | 9.2 | 238 |

| | | | |
|---|---|---|---|
| 120 | Mesoderm-independent regulation of gastrulation movements by the src tyrosine kinase in Xenopus embryo. *Differentiation*, **2001**, 69, 38-48 | 3.5 | 21 |
| 119 | Cloning and characterization of three Xenopus slug promoters reveal direct regulation by Lef/beta-catenin signaling. *Journal of Biological Chemistry*, **2001**, 276, 30350-8 | 5.4 | 134 |
| 118 | Do lung remodeling, repair, and regeneration recapitulate respiratory ontogeny?. *American Journal of Respiratory and Critical Care Medicine*, **2001**, 164, S59-62 | 10.2 | 73 |
| 117 | Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. *American Journal of Pathology*, **2001**, 158, 1955-9 | 5.8 | 370 |
| 116 | Evidence that SPROUTY2 functions as an inhibitor of mouse embryonic lung growth and morphogenesis. *Mechanisms of Development*, **2001**, 102, 81-94 | 1.7 | 186 |
| 115 | Novel mechanisms in murine nitrofen-induced pulmonary hypoplasia: FGF-10 rescue in culture. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2001**, 281, L250-7 | 5.8 | 28 |
| 114 | Le récepteur de type 3 des FGF (FGFR3) : de la chondrodysplasie au cancer de la vessie. *Medecine/Sciences*, **2001**, 17, 1189-1191 | | |
| 113 | Rôle des facteurs de croissance dans la plasticité des épithéliums au cours du développement et dans la carcinogenèse. *Bulletin De L'Academie Nationale De Medecine*, **2001**, 185, 1279-1294 | 0.1 | |
| 112 | Focal adhesions: structure and dynamics. *Biology of the Cell*, **2000**, 92, 477-94 | 3.5 | 249 |
| 111 | Phosphorylation of tyrosine residues 31 and 118 on paxillin regulates cell migration through an association with CRK in NBT-II cells. *Journal of Cell Biology*, **2000**, 148, 957-70 | 7.3 | 238 |
| 110 | Involvement of epidermal growth factor receptor in chemically induced mouse bladder tumour progression. *Carcinogenesis*, **2000**, 21, 2211-8 | 4.6 | 51 |
| 109 | IGF-II promotes mesoderm formation. *Developmental Biology*, **2000**, 227, 133-45 | 3.1 | 61 |
| 108 | Fibroblast growth factor-2. *International Journal of Biochemistry and Cell Biology*, **2000**, 32, 263-7 | 5.6 | 162 |
| 107 | Differential function of N-cadherin and cadherin-7 in the control of embryonic cell motility. *Journal of Cell Biology*, **1999**, 146, 501-16 | 7.3 | 56 |
| 106 | Calponin modulates the exclusion of Otx-expressing cells from convergence extension movements. *Nature Cell Biology*, **1999**, 1, 404-8 | 23.4 | 20 |
| 105 | Relationship between E-cadherin and fibroblast growth factor receptor 2b expression in bladder carcinomas. *Oncogene*, **1999**, 18, 5722-6 | 9.2 | 22 |
| 104 | Tumour suppressive properties of fibroblast growth factor receptor 2-IIIb in human bladder cancer. *Oncogene*, **1999**, 18, 7234-43 | 9.2 | 105 |
| 103 | Epithelial cell plasticity in development and tumor progression. *Cancer and Metastasis Reviews*, **1999**, 18, 31-42 | 9.6 | 162 |

| | | | |
|---|---|---|---|
| 102 | Hepatocellular carcinoma cell lines from diethylnitrosamine phenobarbital-treated rats. Characterization and sensitivity to endothall, a protein serine/threonine phosphatase-2A inhibitor. *Hepatology*, **1999**, 29, 1406-17 | 11.2 | 17 |
| 101 | Characterization of the signaling pathways regulating alpha2beta1 integrin-mediated events by a pharmacological approach. *Cell Adhesion and Communication*, **1999**, 7, 151-65 | | 8 |
| 100 | Cloning and expression pattern of a mouse homologue of drosophila sprouty in the mouse embryo. *Mechanisms of Development*, **1999**, 81, 213-6 | 1.7 | 161 |
| 99 | A novel model to study the dorsolateral migration of melanoblasts. *Mechanisms of Development*, **1999**, 89, 3-14 | 1.7 | 24 |
| 98 | Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. *Nature Genetics*, **1999**, 23, 18-20 | 36.3 | 545 |
| 97 | Slug mRNA is expressed by specific mesodermal derivatives during rodent organogenesis. *Developmental Dynamics*, **1998**, 213, 182-7 | 2.9 | 33 |
| 96 | Medial cell mixing during axial morphogenesis of the amphibian embryo requires cadherin function. *Developmental Dynamics*, **1998**, 213, 248-60 | 2.9 | 11 |
| 95 | Modulation of cytokeratin subtype, EGF receptor, and androgen receptor expression during progression of prostate cancer. *Human Pathology*, **1998**, 29, 1005-12 | 3.7 | 56 |
| 94 | Xenopus cadherin-11 is expressed in different populations of migrating neural crest cells. *Mechanisms of Development*, **1998**, 75, 171-4 | 1.7 | 75 |
| 93 | The mesenchymal cadherin-11 is expressed in restricted sites during the ontogeny of the rat brain in modes suggesting novel functions. *Cell Adhesion and Communication*, **1998**, 6, 431-50 | | 25 |
| 92 | Experimental study of the interaction range and association rate of surface-attached cadherin 11. *Proceedings of the National Academy of Sciences of the United States of America*, **1998**, 95, 9256-61 | 11.5 | 43 |
| 91 | The zinc-finger protein slug causes desmosome dissociation, an initial and necessary step for growth factor-induced epithelial-mesenchymal transition. *Journal of Cell Biology*, **1997**, 137, 1403-19 | 7.3 | 422 |
| 90 | Direct role of the carboxy-terminal cell-binding domain of fibronectin in neural crest cell motility. *Experimental Cell Research*, **1997**, 233, 1-10 | 4.2 | 10 |
| 89 | Decreased expression of keratinocyte growth factor receptor in a subset of human transitional cell bladder carcinomas. *Oncogene*, **1997**, 14, 323-30 | 9.2 | 72 |
| 88 | FGF-2 and FGF-1 expressed in rat bladder carcinoma cells have similar angiogenic potential but different tumorigenic properties in vivo. *Oncogene*, **1997**, 14, 671-6 | 9.2 | 38 |
| 87 | Frequent loss of heterozygosity on chromosome 10q in muscle-invasive transitional cell carcinomas of the bladder. *Oncogene*, **1997**, 14, 3059-66 | 9.2 | 99 |
| 86 | Multiple roles for integrins during development. *Biology of the Cell*, **1997**, 89, 5-11 | 3.5 | 22 |
| 85 | Src and Ras are involved in separate pathways in epithelial cell scattering. *EMBO Journal*, **1997**, 16, 5904-13 | 13 | 122 |

| | | | |
|---|---|---|---|
| 84 | Localization of a neural crest transcription factor, Slug, to mouse chromosome 16 and human chromosome 8. *Mammalian Genome*, **1997**, 8, 872-3 | 3.2 | 13 |
| 83 | Alpha 2 beta 1 integrin is required for the collagen and FGF-1 induced cell dispersion in a rat bladder carcinoma cell line. *Cell Adhesion and Communication*, **1996**, 4, 187-99 | | 54 |
| 82 | Apoptosis in prostate cancer. Molecular basis to study hormone refractory mechanisms. *Annals of the New York Academy of Sciences*, **1996**, 784, 63-9 | 6.5 | 11 |
| 81 | The saga of adhesion molecules. *Journal of Cellular Biochemistry*, **1996**, 61, 489-492 | 4.7 | 7 |
| 80 | Cadherin 11 expression marks the mesenchymal phenotype: towards new functions for cadherins?. *Cell Adhesion and Communication*, **1995**, 3, 115-30 | | 138 |
| 79 | FGF-1 but not FGF-4 secreted by carcinoma cells promotes in vitro and in vivo angiogenesis and rapid tumor proliferation. *Growth Factors*, **1995**, 12, 37-47 | 1.6 | 30 |
| 78 | Contribution of cadherins to directional cell migration and histogenesis in Xenopus embryos. *Cell Adhesion and Communication*, **1995**, 3, 419-40 | | 27 |
| 77 | Tumor progression: the role of cadherins and integrins. *Trends in Molecular Medicine*, **1995**, 1, 84-9 | | 3 |
| 76 | Myoepithelial cell differentiation in the developing mammary gland: progressive acquisition of smooth muscle phenotype. *Developmental Dynamics*, **1995**, 204, 107-17 | 2.9 | 61 |
| 75 | Structure and Function of Cadherins **1995**, 183-208 | | 3 |
| 74 | Modulations of the epithelial phenotype during embryogenesis and cancer progression. *Cancer Treatment and Research*, **1994**, 71, 229-49 | 3.5 | 47 |
| 73 | The operation and efficacy of cryosurgical, nitrous oxide-driven cryoprobe. I. Cryoprobe physical characteristics: their effects on cell cryodestruction. *Cryobiology*, **1994**, 31, 290-304 | 2.7 | 25 |
| 72 | Effect of an inhibitory mutant of the FGF receptor on mesoderm-derived alpha-smooth muscle actin-expressing cells in Xenopus embryo. *Developmental Biology*, **1994**, 164, 374-82 | 3.1 | 13 |
| 71 | Sequence and distribution of Xenopus laevis E-cadherin transcripts. *Cell Adhesion and Communication*, **1993**, 1, 265-77 | | 9 |
| 70 | Adenomyoepithelioma of the breast: fine-needle sampling with histologic, immunohistologic, and electron microscopic analysis. *Diagnostic Cytopathology*, **1993**, 9, 188-93 | 1.4 | 27 |
| 69 | Epithelium-mesenchyme interconversion as example of epithelial plasticity. *Apmis*, **1993**, 101, 257-68 | 3.4 | 74 |
| 68 | Analysis of early reconstitution events in the SCID mouse thymus following rat bone marrow cell transplantation. *Immunology Letters*, **1993**, 37, 63-71 | 4.1 | 5 |
| 67 | In Vivo, Three Distinct Sites of Fibronectin are Essential for its Assembly into Fibrils. *Biology of the Cell*, **1992**, 76, 222-222 | 3.5 | 1 |

| | | | |
|---|---|---|---|
| 66 | The junction between cytokines and cell adhesion. *Current Opinion in Cell Biology*, **1992**, 4, 782-92 | 9 | 64 |
| 65 | E-cadherin expression during the acidic FGF-induced dispersion of a rat bladder carcinoma cell line. *Experimental Cell Research*, **1992**, 201, 347-57 | 4.2 | 59 |
| 64 | Distinct regions of human fibronectin are essential for fibril assembly in an in vivo developing system. *Developmental Dynamics*, **1992**, 194, 63-70 | 2.9 | 32 |
| 63 | N-cadherin transcripts in Xenopus laevis from early tailbud to tadpole. *Developmental Dynamics*, **1992**, 194, 247-60 | 2.9 | 29 |
| 62 | Generation of full-length cDNA recombinant vectors for the transient expression of human fibronectin in mammalian cell lines. *Experimental Cell Research*, **1991**, 193, 331-8 | 4.2 | 19 |
| 61 | Overexpression of nucleoside diphosphate kinase (Nm23) in solid tumours. *European Journal of Cancer & Clinical Oncology*, **1991**, 27, 1302-7 | | 93 |
| 60 | Adhesion systems in embryonic epithelial-to-mesenchyme transformations and in cancer invasion and metastasis. *Exs*, **1991**, 59, 17-34 | | 7 |
| 59 | Cell Adhesion in Morphogenesis **1991**, 349-365 | | |
| 58 | Scattering and motility activities of the extracellular matrix and growth factors on bladder carcinoma cells. *Cancer Investigation*, **1990**, 8, 655-7 | 2.1 | 2 |
| 57 | Modes of cell migration in the vertebrate embryo. *International Review of Cytology*, **1990**, 123, 201-52 | | 16 |
| 56 | Spatio-temporal distribution of the adherens junction-associated molecules vinculin and talin in the early avian embryo. *Cell Differentiation and Development*, **1990**, 30, 55-76 | | 16 |
| 55 | The instructive role of fibronectins in cell migrations during embryonic development. *Annals of the New York Academy of Sciences*, **1990**, 588, 273-80 | 6.5 | 14 |
| 54 | Rat bone marrow cells undergo thymopoiesis in mouse fetal thymic organ culture. *European Journal of Immunology*, **1990**, 20, 2075-81 | 6.1 | 9 |
| 53 | Epithelial cell adhesion mechanisms. *Journal of Membrane Biology*, **1989**, 112, 97-108 | 2.3 | 44 |
| 52 | Reversible transition towards a fibroblastic phenotype in a rat carcinoma cell line. *International Journal of Cancer*, **1989**, 4, 69-75 | 7.5 | 38 |
| 51 | Distribution of fibronectins and laminin in the early pig embryo. *The Anatomical Record*, **1989**, 223, 72-81 | | 27 |
| 50 | Characterization of rat T cell precursors sorted by chemotactic migration toward thymotaxin. *Cell*, **1989**, 56, 1073-83 | 56.2 | 26 |
| 49 | Cell Adhesion in Morphogenesis **1989**, 109-128 | | 6 |

| | | | |
|---|---|---|---|
| 48 | Roles of Fibronectins in Embryogenesis **1989**, 181-212 | | 8 |
| 47 | Adhesion mechanisms in embryogenesis and in cancer invasion and metastasis. *Novartis Foundation Symposium*, **1988**, 141, 48-74 | | 10 |
| 46 | The role of fibronectins in embryonic cell migrations. *Trends in Genetics*, **1988**, 4, 198-203 | 8.5 | 65 |
| 45 | Expression of the HNK-1/NC-1 epitope in early vertebrate neurogenesis. *Cell and Tissue Research*, **1988**, 251, 457-65 | 4.2 | 81 |
| 44 | The migratory behavior of avian embryonic cells does not require phosphorylation of the fibronectin-receptor complex. *FEBS Letters*, **1988**, 230, 181-5 | 3.8 | 16 |
| 43 | Chromosomes in Ewing's sarcoma. I. An evaluation of 85 cases of remarkable consistency of t(11;22)(q24;q12). *Cancer Genetics and Cytogenetics*, **1988**, 32, 229-38 | | 447 |
| 42 | Cell adhesion systems: molecular structure and function in embryogenesis and metastasis. *Advances in Experimental Medicine and Biology*, **1988**, 233, 235-44 | 3.6 | |
| 41 | Expression of the cell-binding domain of human fibronectin in E. coli. Identification of sequences promoting full to minimal adhesive function. *FEBS Letters*, **1987**, 213, 261-4 | 3.8 | 30 |
| 40 | Peptides containing the cell-attachment recognition signal Arg-Gly-Asp prevent gastrulation in Drosophila embryos. *Nature*, **1987**, 325, 348-50 | 50.4 | 80 |
| 39 | Regulation of Development by the Extracellular Matrix **1987**, 1-53 | | 6 |
| 38 | Role of tissue environment and fibronectin in the patterning of neural crest derivatives. *Trends in Neurosciences*, **1986**, 9, 565-570 | 13.3 | 16 |
| 37 | Pathways of avian neural crest cell migration in the developing gut. *Developmental Biology*, **1986**, 116, 439-50 | 3.1 | 98 |
| 36 | The embryonic thymus produces chemotactic peptides involved in the homing of hemopoietic precursors. *Cell*, **1986**, 44, 781-90 | 56.2 | 81 |
| 35 | Cell adhesion mechanisms in gangliogenesis studied in avian embryo and in a model system. *Cell Differentiation*, **1985**, 17, 247-60 | | 13 |
| 34 | What the papers say: Fibronectin in early embryonic development of the vertebrate. *BioEssays*, **1985**, 2, 32-34 | 4.1 | 1 |
| 33 | How do the migratory and adhesive properties of the neural crest govern ganglia formation in the avian peripheral nervous system?. *Journal of Cellular Biochemistry*, **1985**, 27, 189-203 | 4.7 | 40 |
| 32 | Cell migration in the vertebrate embryo: role of cell adhesion and tissue environment in pattern formation. *Annual Review of Cell Biology*, **1985**, 1, 91-113 | | 161 |
| 31 | Adhesive Molecules and their Role During the Ontogeny of the Peripheral Nervous System **1985**, 85-118 | | 2 |

| | | | |
|---|---|---|---|
| 30 | Mechanisms of cell migration in the vertebrate embryo. *Cell Differentiation*, **1984**, 15, 1-15 | | 70 |
| 29 | Identical reactivity of monoclonal antibodies HNK-1 and NC-1: conservation in vertebrates on cells derived from the neural primordium and on some leukocytes. *Cell Differentiation*, **1984**, 14, 223-30 | | 350 |
| 28 | Prevention of gastrulation but not neurulation by antibodies to fibronectin in amphibian embryos. *Nature*, **1984**, 307, 364-7 | 50.4 | 213 |
| 27 | Ontogenetic expression of cell adhesion molecules: L-CAM is found in epithelia derived from the three primary germ layers. *Developmental Biology*, **1984**, 102, 61-78 | 3.1 | 187 |
| 26 | A cell surface marker for neural crest and placodal cells: further evolution in peripheral and central nervous system. *Developmental Biology*, **1984**, 103, 468-81 | 3.1 | 184 |
| 25 | Role of the Extracellular Matrix in Neural Crest Cell Migration **1984**, 139-144 | | 1 |
| 24 | A cell surface determinant expressed early on migrating avian neural crest cells. *Developmental Brain Research*, **1983**, 285, 235-8 | | 139 |
| 23 | In vitro migration of avian hemopoietic cells to the thymus: preliminary characterization of a chemotactic mechanism. *Cell Differentiation*, **1983**, 13, 1-24 | | 35 |
| 22 | Distribution of fibronectin in the early phase of avian cephalic neural crest cell migration. *Developmental Biology*, **1982**, 93, 308-23 | 3.1 | 176 |
| 21 | Pathways and mechanisms of avian trunk neural crest cell migration and localization. *Developmental Biology*, **1982**, 93, 324-43 | 3.1 | 297 |
| 20 | Appearance and distribution of fibronectin during chick embryo gastrulation and neurulation. *Developmental Biology*, **1982**, 94, 337-50 | 3.1 | 108 |
| 19 | Fibronectin in early avian embryos: synthesis and distribution along the migration pathways of neural crest cells. *Cell and Tissue Research*, **1980**, 211, 269-91 | 4.2 | 345 |
| 18 | Antibodies to a neural cell adhesion molecule disrupt histogenesis in cultured chick retinae. *Nature*, **1980**, 285, 488-9 | 50.4 | 158 |
| 17 | The nervous system specific protein D2 is involved in adhesion among neurites from cultured rat ganglia. *FEBS Letters*, **1980**, 111, 39-42 | 3.8 | 121 |
| 16 | Restriction enzyme analysis of satellite DNA components from the bovine genome. *FEBS Journal*, **1978**, 84, 189-95 | | 22 |
| 15 | DNA Sequences in Man **1977**, 35-58 | | 6 |
| 14 | An analysis of eukaryotic genomes by density gradient centrifugation. *Journal of Molecular Biology*, **1976**, 108, 219-35 | 6.5 | 217 |
| 13 | An approach to the organization of eukaryotic genomes at a macromolecular level. *Journal of Molecular Biology*, **1976**, 108, 237-54 | 6.5 | 184 |

| | | | |
|---|---|---|---|
| 12 | A new approach to the study of nucleotide sequences in DNA: the analysis of termini formed by DNases. *Methods in Enzymology*, **1974**, 29, 341-55 | 1.7 | |
| 11 | A new approach to the study of nucleotide sequences in DNAs. *Nucleic Acids Research*, **1974**, 1, 87-96 | 20.1 | 3 |
| 10 | Kinetics of the middle and terminal phases of degradation of DNA by spleen acid DNAase. *FEBS Journal*, **1973**, 38, 423-33 | | 15 |
| 9 | Specificity of spleen acid DNAase. *FEBS Journal*, **1973**, 38, 434-42 | | 25 |
| 8 | Studies on the specificity of an acid deoxyribonuclease from Helix aspersa (Müll.). *FEBS Journal*, **1973**, 40, 133-7 | | 9 |
| 7 | Pyrimidine tracts of the (A + T)-rich satellite DNA from Cancer pagurus. *Nucleic Acids and Protein Synthesis*, **1973**, 312, 633-6 | | 10 |
| 6 | An analysis of the bovine genome by Cs2SO4-Ag density gradient centrifugation. *Journal of Molecular Biology*, **1973**, 80, 177-97 | 6.5 | 192 |
| 5 | The specificity of deoxyribonucleases and their use in nucleotide sequence studies. *Nature: New Biology*, **1973**, 246, 36-40 | | 31 |
| 4 | The mitochondrial genome of wild-type yeast cells. 3. The pyrimidine tracts of mitochondrial DNA. *Journal of Molecular Biology*, **1972**, 65, 207-12 | 6.5 | 45 |
| 3 | Analysis of nucleosides on columns of fractionated sephadex G-10. *Nucleic Acids and Protein Synthesis*, **1971**, 246, 161-8 | | 22 |
| 2 | Integrative analysis and machine learning based characterization of single circulating tumor cells | | 1 |
| 1 | LMO2 is critical for early metastatic events in breast cancer | | 1 |